Ph.D.

Bayer and Cedilla Therapeutics Partner to Develop Targeted Cancer Therapies

Not intended UK Media (IN BRIEF) Bayer and Cedilla Therapeutics have entered into an exclusive license agreement to develop and…

11 months ago

University of Southampton developed new drug with the potential to reverse resistance to immunotherapy

A new drug with the potential to reverse resistance to immunotherapy has been developed by scientists at the University of…

9 years ago

Sandoz announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen’s NEUPOGEN®

Pivotal PIONEER study compared safety and efficacy of the two compounds in the prevention of neutropenia in patients with breast…

9 years ago

Sanofi and subsidiary Genzyme announced that FDA approved LemtradaTM (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS)

Approval Establishes Genzyme’s MS Franchise in the U.S. with Two Approved Products; Follows Global Approvals PARIS, 17-11-2014 — /EuropaWire/ —…

9 years ago

SAP shareholders approved the conversion of legal form to a European stock corporation (Societas Europaea, SE)

Annual General Meeting of Shareholders 2014 Mannheim, Germany,  21-5-2014 — /EuropaWire/ — The Annual General Meeting of Shareholders of SAP AG today…

10 years ago

The global leader in biosimilars Sandoz initiated Phase III clinical trial for biosimilar etanercept

Trial expected to support registration in the U.S. and European Union Sandoz continues to advance biosimilar pipeline with seven Phase…

11 years ago

MedImmune, NGM Biopharmaceuticals in exclusive agreement to discover, develop and commercialise therapies for diabetes and obesity

25-6-2013 — /europawire.eu/ — AstraZeneca today announced that MedImmune, its global biologics research and development arm, and NGM Biopharmaceuticals, Inc. have…

11 years ago